SAB BIO, (“SAB BIO”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback